JAN 19, 2021 8:00 AM PST

The inhibitory role of specific macrophages in RCC

Sponsored by: Visiopharm®
Speaker
  • Head of Immunoanalytics, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany
    Biography
      Dr. Elfriede Noessner is professor at the Ludwig-Maximilians-University of Munich (LMU) in Munich, Germany, and employed by the Helmholtz Zentrum Munich, where she is the Head of Immunoanalytics Research Group. She did her academic training as Diplom-Biologist at the University of Regensburg and Rupprecht-Karls University of Heidelberg, and performed her PhD in Immunology at the LMU in Munich. She is board certified in immunology by the German Society of Immunology. She spent 5 years at Stanford University. Her research topics include the biology of HLA proteins and the antigen presentation; the activation, maintenance and control of T cell responses; and the modulation of T and NK cells, as well as dendritic cells and macrophages in tissue milieus, including cancer.

    Abstract
    Date:  January 19, 2021
    Time: 8:00am (PST),  11:00am (EST)
     
    Only a small subset of patients with clear cell Renal Cell Carcinoma (ccRCC) respond to immunotherapy with checkpoint inhibitors. Research has shown that additional mechanisms of inhibition prevent the majority of patients from successful treatment. Recent studies into the inhibitory role of macrophages portend that these cells are associated with lower survival rate in several different cancer types. In this webinar, Immunologist Prof. Dr. Elfriede Nößner will present her research on specific macrophages in RCC (“ercDCs”) which are associated with poor outcome and their potential as new targets in immune therapy.
     
    Learning Objectives
    • What is known about the role of macrophages in immuno-oncology in general and in RCC specifically
    • What are “ercDCs” and how do they interact with T-Cells in RCC?
    • Which possibilities exist to manipulate the ercDCs?
     
     
    Webinars will be available for unlimited on-demand viewing after live event.
     
     

    Show Resources
    Show Resources
    Attendees
    • See more